![CAR T Cell therapy diagram](/sites/default/files/styles/square_card_l/public/media/images/media-837.png.webp?itok=gy7W6E8X)
First CAR T-cell therapies recommended for approval in Europe
These therapies offer a new treatment option for people with difficult-to-treat B cell lymphomas.
Read the latest news and views from Lymphoma Action.
Use the drop down filter to find the most relevant news for you.
These therapies offer a new treatment option for people with difficult-to-treat B cell lymphomas.
We look forward to Ropinder joining the organisation in August.
How good are blood tests at detecting whether lymphoma is progressing or relapsing? We share the answer from issue 103 of Lymphoma Matters magazine.
Stephen Scowcroft reports back from a biosimilars panel at the European Haematology Association (EHA) Congress 2018.
Promising results for new antibody treatment for B-cell lymphomas in ongoing Hu5F9-G4 clinical trial
Karen, our regional development manager, and her team of daredevils took on the Velocity Zip Slide in Snowdonia to raise funds for us.
This Learning Disability Week, we are seeking feedback to help us develop a new version.
New evidence means the targeted drug can now be used routinely on the NHS for more people with classical Hodgkin lymphoma.
Becky, our senior medical writer, shares some of the discussion from the British Society of Haematology annual meeting.
To mark Carers Week 2018 we highlight the support we offer to those caring for someone with lymphoma.